Cost-effectiveness of insulin detemir compared with NPH insulin in people with type 2 diabetes in Denmark, Finland, Norway, and Sweden

References

• The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
   PubMed Web of Science ®Google Scholar
• Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-53
   PubMed Web of Science ®Google Scholar
• Alvarez-Guisasola F, Yin DD, Nocea G, et al. Association of hypoglycemic symptoms with patients' rating of their health-related quality of life state: a cross sectional study. Health Qual Life Outcomes 2010;8:86
   PubMed Web of Science ®Google Scholar
• Johnston SS, Conner C, Aagren M, et al. Evidence linking hypoglycemic events to an increased risk of acute cardiovascular events in patients with type 2 diabetes. Diabetes Care 2011;34:1164-70
   PubMed Web of Science ®Google Scholar
• Sommerfield AJ, Deary IJ, McAulay V, et al. Moderate hypoglycemia impairs multiple memory functions in healthy adults. Neuropsychology 2003;17:125-32
   PubMed Web of Science ®Google Scholar
• Cryer PE. Hypoglycemia: still the limiting factor in the glycemic management of diabetes. Endocr Pract 2008;14:750-6
   PubMedGoogle Scholar
• Diabetes Association Workgroup on Hypoglycemia, American Diabetes Association. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care 2005;28:1245-9
   Google Scholar
• Brod M, Christensen T, Thomsen TL, et al. The impact of non-severe hypoglycemic events on work productivity and diabetes management. Value Health 2011;14:665-71
   PubMed Web of Science ®Google Scholar
• Hammer M, Lammert M, Mejias SM, et al. Costs of managing severe hypoglycaemia in three European countries. J Med Econ 2009;12:281-90
   PubMedGoogle Scholar
• Pontiroli AE, Miele L, Morabito A. Increase of body weight during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta-analysis. Diabetes Obes Metab 2011;13:1008-19
   PubMed Web of Science ®Google Scholar
• van Dieren S, Czernichow S, Chalmers J, et al. Weight changes and their predictors amongst 11 140 patients with type 2 diabetes in the ADVANCE trial. Diabetes Obes Metab 2012;14:464-9
   PubMed Web of Science ®Google Scholar
• Eeg-Olofsson K, Cederholm J, Nilsson PM, et al. Risk of cardiovascular disease and mortality in overweight and obese patients with type 2 diabetes: an observational study in 13,087 patients. Diabetologia 2009;52:65-73
   PubMed Web of Science ®Google Scholar
• Johnson WD, Brashear MM, Gupta AK, et al. Incremental weight loss improves cardiometabolic risk in extremely obese adults. Am J Med 2011;124:931-8
   Google Scholar
• Ridderstråle M, Gudbjornsdottir S, Eliasson B, et al. Obesity and cardiovascular risk factors in type 2 diabetes: results from the Swedish National Diabetes Register. J Intern Med 2006;259:314-22
   PubMed Web of Science ®Google Scholar
• Gough SC, Kragh N, Ploug UJ, et al. Impact of obesity and type 2 diabetes on health-related quality of life in the general population in England. Diabetes Metab Syndr Obes 2009;2:179-84
   Google Scholar
• Hlatky MA, Chung SC, Escobedo J, et al. The effect of obesity on quality of life in patients with diabetes and coronary artery disease. Am Heart J 2010;159:292-300
   PubMed Web of Science ®Google Scholar
• Peyrot M, Skovlund SE, Landgraf R. Epidemiology and correlates of weight worry in the multinational Diabetes Attitudes, Wishes and Needs study. Curr Med Res Opin 2009;25:1985-93
   PubMed Web of Science ®Google Scholar
• Jendle J, Torffvit O, Ridderstråle M, et al. Willingness to pay for health improvements associated with anti-diabetes treatments for people with type 2 diabetes. Curr Med Res Opin 2010;26:917-23
   PubMed Web of Science ®Google Scholar
• Meneghini LF, Rosenberg KH, Koenen C, et al. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study. Diabetes Obes Metab 2007;9:418-27
   PubMed Web of Science ®Google Scholar
• Valentine WJ, Aagren M, Haglund M, et al. Evaluation of the long-term cost-effectiveness of insulin detemir compared with neutral protamine hagedorn insulin in patients with type 1 diabetes using a basal-bolus regimen in Sweden. Scand J Public Health 2011;39:79-87
   PubMed Web of Science ®Google Scholar
• Philis-Tsimikas A, Charpentier G, Clauson P, et al. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther 2006;28:1569-81
   PubMed Web of Science ®Google Scholar
• Hermansen K, Davies M, Derezinski T, et al. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006;29:1269-74
   PubMed Web of Science ®Google Scholar
• Pieber TR, Draeger E, Kristensen A, et al. Comparison of three multiple injection regimens for Type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir vs. morning plus bedtime NPH insulin. Diabet Med 2005;22:850-7
   PubMed Web of Science ®Google Scholar
• UK Hypoglycaemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia 2007;50:1140-7
   PubMed Web of Science ®Google Scholar
• Fidler C, Elmelund Christensen T, Gillard S. Hypoglycemia: an overview of fear of hypoglycemia, quality-of-life, and impact on costs. J Med Econ 2011;14:646-55
   PubMedGoogle Scholar
• Currie CJ, Poole CD, Woehl A, et al. The health-related utility and health-related quality of life of hospital-treated subjects with type 1 or type 2 diabetes with particular reference to differing severity of peripheral neuropathy. Diabetologia 2006;49:2272-80
   PubMed Web of Science ®Google Scholar
• Lee AJ, Morgan CL, Morrissey M, et al. Evaluation of the association between the EQ-5D (health-related utility) and body mass index (obesity) in hospital-treated people with type 1 diabetes, type 2 diabetes and with no diagnosed diabetes. Diabet Med 2005;22:1482-6
   PubMed Web of Science ®Google Scholar
• Regional Pay and Practitioners Tariff Board Organization Agreement. Agreement about general practice. 2010. http://www.medicinpriser.dk. Accessed March 21, 2012
   Google Scholar
• Hujanen T, Kapiainen S, Tuominen U, et al. The unit cost of healthcare in Finland. 2006. http://asiakas.kela.fi/laakekys_app/LaakekysApplication?kieli=en. Accessed March 21, 2012
   Google Scholar
• The Norwegian Medical Association. Normal tariff for private specialist practice 2011-2012. 2012. www.legemiddelverket.no. Acccessed March 21, 2012
   Google Scholar
• Medicine prices in Sweden. 2012. http://www.tlv.se/beslut/sok-i-databasen. Accessed March 21, 2012
   Google Scholar
• European Central bank. Danish krone (DKK). 2011. http://www.ecb.int/stats/exchange/eurofxref/html/eurofxref-graph-dkk.en.html. Accessed December 6, 2011
   Google Scholar
• European Central Bank. Norwegian krone (NOK). 2011. http://www.ecb.int/stats/exchange/eurofxref/html/eurofxref-graph-nok.en.html. Accessed December 6, 2011
   Google Scholar
• European Central Bank. Swedish krona (SEK). 2011. http://www.ecb.int/stats/exchange/eurofxref/html/eurofxref-graph-sek.en.html. Accessed December 6, 2011
   Google Scholar
• WHO Collaborating Centre for Drug Statistics Methodology. ATCC/DDD Index 2011. Norwegian Institute for Public Health, 2011. http://www.whocc.no/atc_ddd_index/. Accessed July 27, 2011
   Google Scholar
• Keiding H, Færgeman O. Økonomiske konsekvensberegninger og tilskudsregler – belyst ved et eksempel. Ugeskrift for læger 2008;170:651-4
   Google Scholar
• Lundin D. Kostnadseffektivitet som kriterium för subvention av läkemedel – en bra idé? Ekonomiskdebatt 2004;6:32-40
   Google Scholar
• Dagens Medicin. 2012. http://www.dagensmedisin.no/nyheter/kostnader-for-ekstra-levear-forskjell-pa-eldre-og-yngre-/. Accessed May 8, 2012
   Google Scholar
• Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia 2007;50:1140-7
   Google Scholar
• National Institute for Clinical Excellence. Technology Appraisal Guidance No 53. Guidance on the use of long-acting insulin analogues for the treatment of diabetes - insulin glargine. London: National Institute for Clinical Excellence, 2002
   Google Scholar
• Bagust A, Beale S. Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. Health Econ 2005;14:217-30
   PubMed Web of Science ®Google Scholar
• Grima DT, Thompson MF, Sauriol L. Modelling cost effectiveness of insulin glargine for the treatment of type 1 and 2 diabetes in Canada. Pharmacoeconomics 2007;25:253-66
   PubMed Web of Science ®Google Scholar
• McEwan P, Poole C, Tetlow T, et al. Evaluation of the cost-effectiveness of insulin glargine versus NPH insulin for the treatment of type 2 diabetes in the UK. Curr Med Res Opin 2007;23:S21-S31
   Web of Science ®Google Scholar
• Valentine WJ, Erny-Albrecht KM, Ray JA, et al. Therapy conversion to insulin detemir among patients with type 2 diabetes treated with oral agents: a modeling study of cost-effectiveness in the United States. Adv Ther 2007;24:273-90
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research. Guidance for industry diabetes mellitus: developing drugs and therapeutic biologies for treatment and prevention. 2008. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071624.pdf. Accessed September 1, 2011
   Google Scholar
• Matza LS, Boye KS, Yurgin N, et al. Utilities and disutilities for type 2 diabetes treatment-related attributes. Qual Life Res 2007;16:1251-65
   PubMed Web of Science ®Google Scholar
• Donnelly LA, Morris AD, Frier BM, et al. Frequency and predictors of hypoglycaemia in type 1 and insulin-treated type 2 diabetes: a population-based study. Diabet Med 2005;22:749-55
   PubMed Web of Science ®Google Scholar
• Leiter LA, Yale JF, Chiasson JL, et al. Assessment of the impact of fear of hypoglycemic episodes on glycemic and hypoglycemia management. Can J Diabetes 2005;29:186-92
   Google Scholar
• Lundkvist J, Berne C, Bolinder B, et al. The economic and quality of life impact of hypoglycemia. Eur J Health Econ 2005;6:197-202
   PubMedGoogle Scholar
• Heller S. Nocturnal hypoglycaemia. In: Frier BM, Fisher M, eds. Hypoglycaemia in diabetes. 2nd ed. Chichester, UK: John Wiley & Sons Ltd, 2007. p 84-99
   Google Scholar